Pipeline

Our drug pipeline.

We explore nature's hidden bioactive compounds, refine their therapeutic potential, and advance the most promising candidates through each development stage — from in-vitro through Clinical Phase I.

Drug Pipeline

Programs in development

Tap any stage to see program detail. Stages reflect the most advanced ongoing activity for that program.

Program
In-vitro
Pre-clinical
Clinical Phase I

  • NB-A001

    Small molecule — Lead compound

    Solid Tumor (HRD)
    current

  • NB-A002

    Small molecule — NB-A001 derivative

    Solid Tumor (HRD)
    current

  • NB-A007

    Small molecule — NB-A001 derivative

    Solid Tumor (HRD)
    current

  • NB-B101

    Small molecule — Lead compound

    Solid Tumor (HRD)
    current

  • NB-B102

    Small molecule — NB-B101 derivative

    Solid Tumor (HRD)
    current

  • NB-B107

    Small molecule — NB-B101 derivative

    Solid Tumor (HRD)
    current

  • NB-C201

    Small molecule — Lead compound

    Metabolic Diseases
    current

  • NB-H7

    Herb identified, extracting API

    CVD
    current

  • NB-H2

    Herb identified, extracting API

    Fatty Liver Diseases
    current

  • NB-H5

    Herb identified, extracting API

    Obesity
    current

In-vitro

Cell-based screening, target validation, lead identification.

Pre-clinical

Lead optimisation, in vivo PK/PD, ADMET and tox studies.

Clinical Phase I

First-in-human safety and dose-finding.

Revolutionizing cancer treatment

First-in-class small molecules for HRD-positive, chemo-resistant cancers

Molecule: NB-A002

Problem

HRD-positive cancers resist standard treatments like PARP inhibitors and platinum-based chemotherapy, leading to poor patient outcomes. New solutions are urgently needed.

Solution

NB-A002 — our novel molecules derived from tropical medicinal plants. Engineered to trigger synthetic lethality via Transcription-Replication Conflicts, they effectively target DNA damage response deficient cancers.